We are live on
!
Find out more
CASI
CASI Pharmaceuticals
CASI
CASI
Delisted
CASI was delisted on the 25th of February, 2026.
57 hedge funds and large institutions have $80.8M invested in CASI Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 16 increasing their positions, 3 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
433% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 3
290% more capital invested
Capital invested by funds: $20.7M → $80.8M (+$60.1M)
93% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 14
30% more funds holding
Funds holding: 44 → 57 (+13)
0.43% more ownership
Funds ownership: 0.71% → 1.14% (+0.43%)
Holders
57
Holders Change
+13
Holders Change %
+29.55%
% of All Funds
1.3%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
27
Increased
16
Reduced
3
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
BlackRock
New York
|
+$15.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.84M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$3.32M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.17M |
| 5 |
WSC
Wellington Shields & Co
New York
|
+$2.2M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$2.78M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$881K |
| 3 |
Goldman Sachs
New York
|
-$743K |
| 4 |
Barclays
London,
United Kingdom
|
-$286K |
| 5 |
LCM
Laurion Capital Management
New York
|
-$232K |
